To the full analysis
InfuSystem Holdings stock: valuation and P/E
INFUInfuSystem Holdings trades at a P/E of 33 (Medical (Devices) median 29.1, own median of recent years 52.4).
P/E
33
P/S
2.1
P/B
4.86
PEG
2.45
Against its own valuation history
Each fiscal year is shown with its P/E on the year-end date, using the price at the time.
P/E
33
Median of prior years
52.4
Reading
cheaper than usual
P/E at each fiscal year end
Figures as a table
| Year | P/E |
|---|---|
| 2019 | 123.6 |
| 2020 | 21.8 |
| 2021 | 243.3 |
| 2022 | 9,644.4 |
| 2023 | 263.5 |
| 2024 | 76.8 |
| 2025 | 28 |
Data status and sources
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 8 Aug 2025)
- Valuation signal Undervalued since 11 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.